Increase in Extended Content Label Orders Due to Coronavirus-Related Clinical Trials
Luminer, a labeling solutions provider specializing in extended content labels (ECLs) for pharmaceutical ethical and OTC packaging, clinical trials and more, has seen a significant rise in demand for extended content labels for clinical trials — several of which deal with ongoing development for drugs related to the coronavirus pandemic. Another pharma niche seeing a spike in orders are labels for over-the-counter medications that mitigate flu-like symptoms. A number of these products, especially those in small packaging, require multi-page labels to meet regulatory requirements.
Luminer’s segmented upticks point to the pharma industry’s evolving needs as the country continues to grapple with the COVID-19 crisis. The sudden prioritization of drugs to combat coronavirus symptoms, as well as the search for an effective vaccine, has led to some labeling formats being particularly sought-after.